Asmasal SDU

Asmasal SDU

salbutamol

Manufacturer:

Teva Pharma

Distributor:

DKLL
Full Prescribing Info
Contents
Salbutamol.
Description
Each mL of Asmasal SDU respirator solution contains salbutamol sulfate equivalent to salbutamol USP 0.1% or 1 mg.
Indications/Uses
Asmasal SDU respirator solution is indicated for use in the treatment to acute severe asthma and bronchospasm.
Dosage/Direction for Use
Adults and Children: A starting dose of Asmasal SDU respirator solution is 2.5 mg and may be increased to 5 mg. Treatment may be repeated four times daily. Asmasal SDU is intended to be used undiluted except in case of prolonged delivery time is desirable (more than 10 minutes) dilution using normal saline for injection as a diluent may be required.
In some case may be used by endotracheal tube, mouthpiece or face mask. Intermittent positive pressure ventilation may be used if necessary.
Overdosage
The preferred antidote for overdosage with Asmasal SDU respirator solution is a cardioselective beta-adrenergic blocker (e.g. acebutalol, atenolol, metoprolol) a cardioselective beta-adrenergic blocker should be used with caution because bronchospasm may occur.
Contraindications
In patients with a history of hypersensitivity to any of their components.
Although intravenous salbutamol and occasionally salbutamol tablets are used in the management of premature labour uncomplicated by conditions such as placenta praevia, antepartum haemorrhage or toxaemia of pregnancy, inhaled salbutamol presentations are not appropriate for managing premature labour. Salbutamol presentations should not be used for threatened abortion.
Special Precautions
Caution in patients known to have received large doses of other sympathomimetic drugs.
Caution is patients with thyrotoxicosis.
Asmasal SDU respirator solution is to be used with respirator or nebuliser under the direction of a physician. The solution must not be injected.
As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.
Potentially serious hypokalaemia may result from β2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.
Acute angle closure glaucoma with a combination of nebulised salbutamol and ipratropium bromide. A combination of nebulised salbutamol with nebulised anticholinergics should therefore be used cautiously. Patients should be warned not to let the solution of mist enter the eye.
Use in Pregnancy & Lactation: If unnecessary, this drug should not be considered in Pregnancy and Lactation.
As salbutamol is probably secreted in breast milk its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.
Use In Pregnancy & Lactation
If unnecessary, this drug should not be considered in Pregnancy and Lactation.
As salbutamol is probably secreted in breast milk its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.
Adverse Reactions
Tremor, Headache. Peripheral vasodilation and a compensatory small increase in heart rate. Muscle cramps. Hyperactivity in children. Tachycardia may occur.
Caution For Usage
Dilution: Asmasal SDU may be diluted with Sodium chloride injection (normal saline). Any unused solution in the chamber of the nebuliser must be discarded.
Instructions for Use of Asmasal SDU: Tear off tube from the card.
Twist the tip off to open.
Keep un-opened tubes within pouches.
Storage
This drug should be stored below 25°C and protected from light. The contents should be used immediately after the tube is opened. After use, discard any remaining solution.
ATC Classification
R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Inhalation soln 0.1% x 2.5 mL x 21's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in